Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer

Zhaomei Mu, Chun Wang, Zhong Ye, Giovanna Rossi, Carl Sun, Ling Li, Zhu Zhu, Hushan Yang, Massimo Cristofanilli

Research output: Contribution to journalArticle

Abstract

Purpose: Circulating cancer associated macrophage-like cells (CAMLs) have been detected in the peripheral blood of patients with solid tumors including breast cancer. However, the prognostic relevance of CAMLs in metastatic breast cancer (MBC) has not been evaluated. In the present study, we aimed to measure CAMLs and circulating tumor cells (CTCs) at baseline and examine their prognostic value in patients with MBC. Methods: Peripheral blood samples from 127 MBC patients were collected at baseline before starting a new treatment. The detection and enumeration of CAMLs and CTCs in 7.5 ml whole blood were performed using the CellSearch™ system. The associations of CAMLs and CTCs with the progression-free survival (PFS) and overall survival (OS) in the patients were evaluated using Kaplan–Meier curves and Cox proportional hazards modeling. Results: Among 127 MBC patients, 21 (16.5%) were detected with CAMLs and 38 (29.9%) had elevated CTCs (≥5 CTCs/7.5 ml). Patients with CAMLs at baseline had worse PFS and OS with an adjusted hazard ratio (HR) of 1.75 (95% CI 1.03–2.98, P = 0.0374) and 3.75 (95% CI 1.52–9.26, P = 0.0042), compared to patients without CAMLs. Compared with patients with <5 CTCs and without CAMLs, patients with <5 CTCs and with CAMLs, with ≥5 CTCs but without CAMLs, or with ≥5 CTCs and with CAMLs, had an increasing trend of risk of disease progression (HR = 0.84, 3.42 and 4.04 respectively, P for trend <0.0001) and death (HR = 2.66, 6.14, and 9.13, respectively, P for trend <0.0001). Conclusion: Baseline enumeration of individual CAMLs is an independent indicator for MBC patients’ survival. Evaluation of CAMLs in peripheral blood might provide a potential biomarker with additional prognostic values over CTC enumeration alone in MBC patients.

Original languageEnglish
Pages (from-to)733-741
Number of pages9
JournalBreast Cancer Research and Treatment
Volume165
Issue number3
DOIs
Publication statusPublished - Oct 1 2017

Fingerprint

Circulating Neoplastic Cells
Macrophages
Breast Neoplasms
Neoplasms
Disease-Free Survival
Survival
Disease Progression
Biomarkers

Keywords

  • Circulating cancer associated macrophage-like cells (CAMLs)
  • Circulating tumor cells (CTCs)
  • Metastatic breast cancer (MBC)
  • Overall survival (OS)
  • Prognosis
  • Progression-free survival (PFS)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer. / Mu, Zhaomei; Wang, Chun; Ye, Zhong; Rossi, Giovanna; Sun, Carl; Li, Ling; Zhu, Zhu; Yang, Hushan; Cristofanilli, Massimo.

In: Breast Cancer Research and Treatment, Vol. 165, No. 3, 01.10.2017, p. 733-741.

Research output: Contribution to journalArticle

Mu, Z, Wang, C, Ye, Z, Rossi, G, Sun, C, Li, L, Zhu, Z, Yang, H & Cristofanilli, M 2017, 'Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer', Breast Cancer Research and Treatment, vol. 165, no. 3, pp. 733-741. https://doi.org/10.1007/s10549-017-4372-8
Mu, Zhaomei ; Wang, Chun ; Ye, Zhong ; Rossi, Giovanna ; Sun, Carl ; Li, Ling ; Zhu, Zhu ; Yang, Hushan ; Cristofanilli, Massimo. / Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer. In: Breast Cancer Research and Treatment. 2017 ; Vol. 165, No. 3. pp. 733-741.
@article{f58ca94845a245d4bf1eba3f8603ba2c,
title = "Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer",
abstract = "Purpose: Circulating cancer associated macrophage-like cells (CAMLs) have been detected in the peripheral blood of patients with solid tumors including breast cancer. However, the prognostic relevance of CAMLs in metastatic breast cancer (MBC) has not been evaluated. In the present study, we aimed to measure CAMLs and circulating tumor cells (CTCs) at baseline and examine their prognostic value in patients with MBC. Methods: Peripheral blood samples from 127 MBC patients were collected at baseline before starting a new treatment. The detection and enumeration of CAMLs and CTCs in 7.5 ml whole blood were performed using the CellSearch™ system. The associations of CAMLs and CTCs with the progression-free survival (PFS) and overall survival (OS) in the patients were evaluated using Kaplan–Meier curves and Cox proportional hazards modeling. Results: Among 127 MBC patients, 21 (16.5{\%}) were detected with CAMLs and 38 (29.9{\%}) had elevated CTCs (≥5 CTCs/7.5 ml). Patients with CAMLs at baseline had worse PFS and OS with an adjusted hazard ratio (HR) of 1.75 (95{\%} CI 1.03–2.98, P = 0.0374) and 3.75 (95{\%} CI 1.52–9.26, P = 0.0042), compared to patients without CAMLs. Compared with patients with <5 CTCs and without CAMLs, patients with <5 CTCs and with CAMLs, with ≥5 CTCs but without CAMLs, or with ≥5 CTCs and with CAMLs, had an increasing trend of risk of disease progression (HR = 0.84, 3.42 and 4.04 respectively, P for trend <0.0001) and death (HR = 2.66, 6.14, and 9.13, respectively, P for trend <0.0001). Conclusion: Baseline enumeration of individual CAMLs is an independent indicator for MBC patients’ survival. Evaluation of CAMLs in peripheral blood might provide a potential biomarker with additional prognostic values over CTC enumeration alone in MBC patients.",
keywords = "Circulating cancer associated macrophage-like cells (CAMLs), Circulating tumor cells (CTCs), Metastatic breast cancer (MBC), Overall survival (OS), Prognosis, Progression-free survival (PFS)",
author = "Zhaomei Mu and Chun Wang and Zhong Ye and Giovanna Rossi and Carl Sun and Ling Li and Zhu Zhu and Hushan Yang and Massimo Cristofanilli",
year = "2017",
month = "10",
day = "1",
doi = "10.1007/s10549-017-4372-8",
language = "English",
volume = "165",
pages = "733--741",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "3",

}

TY - JOUR

T1 - Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer

AU - Mu, Zhaomei

AU - Wang, Chun

AU - Ye, Zhong

AU - Rossi, Giovanna

AU - Sun, Carl

AU - Li, Ling

AU - Zhu, Zhu

AU - Yang, Hushan

AU - Cristofanilli, Massimo

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Purpose: Circulating cancer associated macrophage-like cells (CAMLs) have been detected in the peripheral blood of patients with solid tumors including breast cancer. However, the prognostic relevance of CAMLs in metastatic breast cancer (MBC) has not been evaluated. In the present study, we aimed to measure CAMLs and circulating tumor cells (CTCs) at baseline and examine their prognostic value in patients with MBC. Methods: Peripheral blood samples from 127 MBC patients were collected at baseline before starting a new treatment. The detection and enumeration of CAMLs and CTCs in 7.5 ml whole blood were performed using the CellSearch™ system. The associations of CAMLs and CTCs with the progression-free survival (PFS) and overall survival (OS) in the patients were evaluated using Kaplan–Meier curves and Cox proportional hazards modeling. Results: Among 127 MBC patients, 21 (16.5%) were detected with CAMLs and 38 (29.9%) had elevated CTCs (≥5 CTCs/7.5 ml). Patients with CAMLs at baseline had worse PFS and OS with an adjusted hazard ratio (HR) of 1.75 (95% CI 1.03–2.98, P = 0.0374) and 3.75 (95% CI 1.52–9.26, P = 0.0042), compared to patients without CAMLs. Compared with patients with <5 CTCs and without CAMLs, patients with <5 CTCs and with CAMLs, with ≥5 CTCs but without CAMLs, or with ≥5 CTCs and with CAMLs, had an increasing trend of risk of disease progression (HR = 0.84, 3.42 and 4.04 respectively, P for trend <0.0001) and death (HR = 2.66, 6.14, and 9.13, respectively, P for trend <0.0001). Conclusion: Baseline enumeration of individual CAMLs is an independent indicator for MBC patients’ survival. Evaluation of CAMLs in peripheral blood might provide a potential biomarker with additional prognostic values over CTC enumeration alone in MBC patients.

AB - Purpose: Circulating cancer associated macrophage-like cells (CAMLs) have been detected in the peripheral blood of patients with solid tumors including breast cancer. However, the prognostic relevance of CAMLs in metastatic breast cancer (MBC) has not been evaluated. In the present study, we aimed to measure CAMLs and circulating tumor cells (CTCs) at baseline and examine their prognostic value in patients with MBC. Methods: Peripheral blood samples from 127 MBC patients were collected at baseline before starting a new treatment. The detection and enumeration of CAMLs and CTCs in 7.5 ml whole blood were performed using the CellSearch™ system. The associations of CAMLs and CTCs with the progression-free survival (PFS) and overall survival (OS) in the patients were evaluated using Kaplan–Meier curves and Cox proportional hazards modeling. Results: Among 127 MBC patients, 21 (16.5%) were detected with CAMLs and 38 (29.9%) had elevated CTCs (≥5 CTCs/7.5 ml). Patients with CAMLs at baseline had worse PFS and OS with an adjusted hazard ratio (HR) of 1.75 (95% CI 1.03–2.98, P = 0.0374) and 3.75 (95% CI 1.52–9.26, P = 0.0042), compared to patients without CAMLs. Compared with patients with <5 CTCs and without CAMLs, patients with <5 CTCs and with CAMLs, with ≥5 CTCs but without CAMLs, or with ≥5 CTCs and with CAMLs, had an increasing trend of risk of disease progression (HR = 0.84, 3.42 and 4.04 respectively, P for trend <0.0001) and death (HR = 2.66, 6.14, and 9.13, respectively, P for trend <0.0001). Conclusion: Baseline enumeration of individual CAMLs is an independent indicator for MBC patients’ survival. Evaluation of CAMLs in peripheral blood might provide a potential biomarker with additional prognostic values over CTC enumeration alone in MBC patients.

KW - Circulating cancer associated macrophage-like cells (CAMLs)

KW - Circulating tumor cells (CTCs)

KW - Metastatic breast cancer (MBC)

KW - Overall survival (OS)

KW - Prognosis

KW - Progression-free survival (PFS)

UR - http://www.scopus.com/inward/record.url?scp=85021906767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021906767&partnerID=8YFLogxK

U2 - 10.1007/s10549-017-4372-8

DO - 10.1007/s10549-017-4372-8

M3 - Article

AN - SCOPUS:85021906767

VL - 165

SP - 733

EP - 741

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -